# Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

> **NCT03908307** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 150 (actual)

## Conditions studied

- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** OZURDEX

## Key facts

- **NCT ID:** NCT03908307
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-25
- **Primary completion:** 2021-09-26
- **Final completion:** 2021-09-26
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03908307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03908307, "Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03908307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*